Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2022 | Story Andrè Damons | Photo Andrè Damons
Prof Motlalepula Matsabisa
This week, Prof Motlalepula Matsabisa, will give a keynote speech on Indigenous Knowledge Systems (IKS) and Health during a session at the eighth edition of the UNGA77 Science Summit around the 77th United Nations General Assembly (SSUNGA77).

Prof Motlalepula Matsabisa, Director of Pharmacology at the University of the Free State (UFS), has been invited to give a keynote speech on Indigenous Knowledge Systems (IKS) and Health during a session at the eighth edition of the UNGA77 Science Summit around the 77th United Nations General Assembly (SSUNGA77).

While in New York, Prof Matsabisa will also meet with officials from the Wellcome Trust – a global charitable foundation – where he will present a strong and compelling motivation for the Wellcome Trust to invest in traditional medicines. Says Prof Matsabisa: “I will deliver a compelling message for investment to be made in scientific research and development around traditional medicines. This development will be piloted in a hub-and-spoke model based on the African economic blocks, with the hub being in South Africa. The returns on the investment put in this initiative will be massive for the African continent, both socially and economically, and I believe it will lead to self-sustainability and Africa being a supplier of innovations based on the science of traditional medicines.” 

SSUNGA77 is organised by Intelligence in Science and will take place from 13 to 30 September 2022. It will bring together thought leaders, scientists, technologists, innovators, policy makers, decision makers, regulators, financiers, philanthropists, journalists and editors, and community leaders to increase health science and citizen collaboration across a broad spectrum of themes, including ICT, nutrition, agriculture, health, IKS, and the environment.

Prof Matsabisa, an expert in African traditional medicine (ATM) and Chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19 (REACT), is also the convener of this session, following his successful proposal for such a session. The session will take place in person on 20 September at the UN headquarters in New York. It is an official side event of the UN General Assembly’s 77th anniversary and will be co-sponsored by the permanent missions of Ireland, Spain, South Africa, Brazil, and Bangladesh to the UN.

His message at Science Summit

“At the end of the summit, we are to make recommendations to the UN, EU, and AU on IKS and health developmental matters. This is exciting and nerve-wracking for me, but I will remain calm knowing that I have a message to deliver to the highest global decision-making body. There can be nothing greater than presenting my talk and proposals for consideration to such a body.” 

“I will convey three simple messages, namely the importance of traditional medicines in contributing to universal health coverage, the need for Africa – through the heads of state and governments – to take seriously the local manufacturing of traditional medicines for industrialisation, economic emancipation, and responding to poverty and inequality. The third message is the need for sustained and adequate financial support by African ministries of health for the development, commercialisation, and market access to quality and well-researched, safe, and effective traditional medicines in order to contribute to priority diseases as well as responding to pandemics,” says Prof Matsabisa. 

According to him, this address at SSUNGA77 is a chance to correctly position the story on IKS with arguments based on good scientific evidence. “It means we are getting much closer to the institutionalisation and formal economic contribution of IKS to health, and that the African IKS health system is getting international recognition and acceptance,” he says.
Prof Matsabisa says he hopes the message will emerge clearly from his talk that Africa has the resources for raw materials and that the science, as well as the infrastructure, exists to develop IKS and to contribute to new health products. The spin-off is the industrialisation, job creation, and wealth generation that Africa can offer to the rest of the world.

Overall information on the summit is available here

News Archive

UFS cardiac team leading with project
2017-05-31

 Description: Cardiac team read more Tags: Cardiac team read more

Prof Peter Schultheiss of the Charité University in Berlin,
Germany, visited the Robert WM Frater Centre for
Cardiovascular Research at the UFS for a study regarding
cardiomyopathy, a significant cause of fatal heart failure
among Africans. From the left are Dr Glen Taylor,
Dr Danie Buys, Prof Makoali Makatoko,
Prof Schultheiss and Prof Francis Smit.
Photo: Rulanzen Martin

A team of cardiac doctors associated with the Robert WM Frater Cardiovascular Research Centre at the University of the Free State’s (UFS) Faculty of Health Sciences has commenced with a pioneering research project regarding idiopathic dilating cardiomyopathy.  

An Afrocentric research focus
Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS and Head of the Frater Centre, describes dilating cardiomyopathy as a heart muscle disease that is quite common, particularly among people of African descent. The disease weakens the heart muscle, which in turn leads to heart failure.

“To date there is no curable treatment for this condition and 50% of patients that have shown heart failure, died within a period of five years. The causes of this condition have been unknown in the majority of patients. But over the past few years major strides have been made where virus infections of the heart muscle or myocarditis have been identified as a possible underlying cause. Various genetic diseases are also linked to it,” says Prof Smit.

International collaborations ensure success
According to Prof Smit, the project is being run in conjunction with Prof Heinz-Peter Schultheiss of the Charité University and the Institute for Cardiac Diagnostics and Therapy in Berlin, Germany.

“We have been working on the project over the past 18 months and I have twice visited Prof Schultheiss in Germany. He is now visiting us in Bloemfontein. We have established a collaborative project focused on patients in central South Africa”.
Prof Schultheiss is a world leader regarding the diagnosis, pathology and treatment of dilating cardiomyopathy, says Prof Smit.

“He brings a lifetime of research experience to Bloemfontein and is internationally renowned as the father of myocardial or heart muscle biopsies.

“His pioneering work on the discipline has led to diagnostic accuracy that has induced purposeful and personalised treatment of dilating cardiomyopathy and has brought about dramatic changes in some subsets of patients’ life expectancy and their cure.”

Solving problems close to home
According to Prof Mokoali Makatoko, Head of the Department of Cardiology, there are more than 1500 new cases of heart failure identified annually at the Universitas Academic Hospital, of which approximately 30% are attributed to cardiomyopathy. “With the use of endomyocardial biopsies the team hopes to treat viruses unique to Southern Africa as well as other underlying causes of dilating cardiomyopathy.”

Prof Stephen Brown, Head of Paediatric Cardiology at the Universitas Academic Hospital, says children suffering from this disease never reach a mature age and those under his supervision will also be undergoing these tests. Various other departments at the UFS will also participate in this project. Profs Makatoko and Brown did the first four endomyocardial biopsies under the management of Prof Schultheiss during the past week. The results will be available in the coming weeks after which the project will be officially launched and patient recruitment will start in earnest.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept